Business Briefing: Drug Approval, Defense Deal, and a Wave of Listings
The FDA cleared Tecentriq for stage III colon cancer, while Raytheon secured a $6.3 billion missile defense contract. Capital markets were active as TRex Bio and Retension Pharmaceuticals priced IPOs, and Green AI Cloud and Quantisimo moved toward Nasdaq listings through SPAC deals. Crescent Energy also launched a large share offering.
The FDA cleared Tecentriq for stage III colon cancer, adding a treatment option in that setting. RTX’s Raytheon unit received a five-year missile-defense award worth $6.3 billion. In listings, TRex Bio priced 8,333,334 shares at $14, implying about $116.7 million in gross proceeds, while Retension Pharmaceuticals set its IPO at $12 per share.
Green AI Cloud agreed to a SPAC deal valuing it at $300 million, and Quantisimo, formed by WISeKey and SEALSQ, will merge with GigCapital8 for a Nasdaq listing. Crescent Energy offered 80 million shares at $12.50, implying roughly $1 billion. Other deals included IIPR’s $50 million preferred sale and H.B. Fuller’s $850 million notes due 2034 at 7.625%.
Patients with stage III colon cancer could see another option, though access and outcomes may depend on cost, coverage, and clinical use. The defense award may support jobs and suppliers tied to Raytheon while shaping security debates. The IPO and SPAC activity could broaden public-market access for biotech, AI, and energy firms, potentially funding growth and hiring, but investors may face volatility if listings underperform. Large offerings and debt deals may influence sector capital costs and corporate strategies.